BioCentury | Nov 6, 2020
Targets & Mechanisms

Data Byte: newly identified host factors that regulate ACE2 expression

Several recent publications highlighting host factors that modulate ACE2 expression point to possible new targets for COVID-19 therapies.  ACE2 and TMPRSS2 are the most common host targets of...
BioCentury | Oct 26, 2020
Emerging Company Profile

Serial dealmaker Glick to lead cancer start-up Scorpion with familiar VCs supplying $108M

A VC syndicate that backed IFM and serial dealmaker Gary Glick has launched precision oncology start-up Scorpion, where Glick will be president and CEO, with $108 million in series A funding. Scorpion...
BioCentury | Oct 10, 2020
Product Development

Next-generation CRISPR technologies keep on building

The Nobel Prize in Chemistry for CRISPR-based gene editing, announced this week, arrives at a time that’s likely to be just chapter one in the field’s history, with the first CRISPR tools yet...
BioCentury | Oct 7, 2020
Tools & Techniques

Doudna and Charpentier, CRISPR pioneers behind a spate of gene editing companies, awarded Nobel Prize

Jennifer Doudna and Emmanuelle Charpentier have won the 2020 Nobel Prize in Chemistry eight years after their joint discovery that the CRISPR-Cas9 bacterial immune defense system can be harnessed...
BioCentury | Oct 6, 2020
Management Tracks

BioMarin, Sanofi tap new execs for early R&D positions

BioMarin and Sanofi each have new leaders of their early R&D teams, as the biotech has made a high-profile hire while the French pharma has promoted from within to replace two executives who are leaving...
BioCentury | Oct 6, 2020
Emerging Company Profile

Scribe: engineering CRISPR’s next generation

Scribe is carving out a new space in the gene editing landscape with a next-generation version of the technology from Jennifer Doudna’s lab that substitutes engineered CRISPR enzymes for their natural counterparts. Scribe Therapeutics Inc....
BioCentury | Sep 29, 2020
Distillery Therapeutics

Blocking glucocorticoid signaling to increase checkpoint inhibitor sensitivity

DISEASE CATEGORY: Cancer INDICATION: Melanoma; colorectal cancer Inhibiting the glucocorticoid receptor could treat melanoma and colorectal cancer and enhance sensitivity to checkpoint blockade. In...
BioCentury | Sep 16, 2020
Emerging Company Profile

Graphite launches with $45M series A to use CRISPR-Cas9 for targeted gene integration

Matthew Porteus’ latest gene editing play Graphite Bio launched with a $45 million series A round and a technology to tackle one of the biggest challenges in CRISPR-based gene editing: inserting corrected...
BioCentury | Sep 11, 2020
Politics, Policy & Law

Broad Institute holds its ground in CRISPR IP dispute

The question of who first invented CRISPR gene editing technology should finally be answered late next year, and the latest development in the IP battle suggests the Broad Institute holds the dominant position leading into...
BioCentury | Aug 1, 2020
Tools & Techniques

Lurie winner and incoming Genentech R&D chief Aviv Regev looks to gene programs to untangle complex diseases

Single cell pioneer Aviv Regev thinks the gene networks revealed by the technology are on the verge of delivering new ways to attack disease biology. Her emphasis is on the idea that uncovering how genes...
Items per page:
1 - 10 of 989